Tamarind seeds join the fight against dry eye

Article

Tamarind seed polysaccharide (TSP) 0.5% and 1% offers at least equivalent relief from dry eye symptoms as hyaluronic acid (HA), according to a study published online by BMC Ophthalmology in March.

Tamarind seed polysaccharide (TSP) 0.5% and 1% offers at least equivalent relief from dry eye symptoms as hyaluronic acid (HA), according to a study published online by BMC Ophthalmology in March.

Maurizio Rolando and Cristiana Valente from the University of Genoa, Italy compared the activity of TSP and HA in an open-label, randomized, single centre clinical study. Thirty subjects were randomized to receive three or more applications per day of either TSP 0.5%, TSP 1% or HA 0.2% over a 90 day period. Tolerability was assessed by visual analogue scale (VAS).

TSP 0.5% and 1% were comparable to HA in terms of tolerability, stability of the pre-corneal tear film and corneal and conjunctival staining. However, TSP was found to be more beneficial than HA in terms of addressing subjective symptoms such as trouble blinking, ocular burning and foreign body sensation.

It was concluded that TSP is at least as effective against dry eye as HA and the authors suggest that larger studies are required to further establish the efficacy and safety of the compound as a treatment for dry eye syndrome.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.